Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 14 | 2024 | 429 | 2.760 |
Why?
|
| Osteosarcoma | 12 | 2024 | 259 | 2.350 |
Why?
|
| Antineoplastic Agents | 6 | 2022 | 1677 | 0.740 |
Why?
|
| Hypersplenism | 1 | 2020 | 2 | 0.730 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2020 | 10 | 0.720 |
Why?
|
| Disclosure | 1 | 2021 | 153 | 0.690 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2019 | 24 | 0.640 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 230 | 0.620 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2018 | 11 | 0.600 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 225 | 0.590 |
Why?
|
| Retinal Neoplasms | 1 | 2018 | 98 | 0.550 |
Why?
|
| Lung Neoplasms | 4 | 2019 | 1622 | 0.540 |
Why?
|
| Wilms Tumor | 1 | 2018 | 116 | 0.540 |
Why?
|
| Hepatoblastoma | 1 | 2018 | 214 | 0.490 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2021 | 874 | 0.460 |
Why?
|
| Sarcoma, Ewing | 3 | 2024 | 113 | 0.460 |
Why?
|
| Neuroblastoma | 1 | 2019 | 511 | 0.450 |
Why?
|
| RNA, Long Noncoding | 3 | 2022 | 210 | 0.440 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 431 | 0.440 |
Why?
|
| Neoplasms | 4 | 2022 | 2752 | 0.430 |
Why?
|
| Rhabdomyosarcoma | 3 | 2021 | 199 | 0.420 |
Why?
|
| Receptor, ErbB-2 | 3 | 2015 | 497 | 0.420 |
Why?
|
| T-Lymphocytes | 4 | 2017 | 1679 | 0.420 |
Why?
|
| Neoplasm Metastasis | 5 | 2024 | 655 | 0.410 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 1222 | 0.390 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 215 | 0.360 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 295 | 0.320 |
Why?
|
| Child | 16 | 2024 | 24108 | 0.320 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2022 | 366 | 0.310 |
Why?
|
| Cancer Survivors | 2 | 2020 | 187 | 0.290 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 1387 | 0.290 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2024 | 1889 | 0.270 |
Why?
|
| Immunotherapy | 3 | 2017 | 662 | 0.260 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 1674 | 0.250 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2011 | 790 | 0.250 |
Why?
|
| Humans | 29 | 2024 | 122409 | 0.240 |
Why?
|
| Mice, SCID | 4 | 2019 | 572 | 0.240 |
Why?
|
| Methotrexate | 2 | 2019 | 341 | 0.230 |
Why?
|
| Mice, Inbred NOD | 3 | 2019 | 286 | 0.230 |
Why?
|
| Adolescent | 11 | 2024 | 18971 | 0.220 |
Why?
|
| MicroRNAs | 2 | 2023 | 837 | 0.210 |
Why?
|
| Tripartite Motif-Containing Protein 28 | 1 | 2022 | 16 | 0.210 |
Why?
|
| Proton Therapy | 1 | 2024 | 120 | 0.210 |
Why?
|
| Cell Line, Tumor | 5 | 2024 | 3301 | 0.200 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2022 | 16 | 0.200 |
Why?
|
| Stroke Volume | 2 | 2022 | 448 | 0.200 |
Why?
|
| Electron Transport Complex I | 1 | 2021 | 32 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 717 | 0.200 |
Why?
|
| Rothmund-Thomson Syndrome | 1 | 2021 | 48 | 0.190 |
Why?
|
| RecQ Helicases | 1 | 2021 | 62 | 0.190 |
Why?
|
| MyoD Protein | 1 | 2021 | 21 | 0.190 |
Why?
|
| Ribonuclease III | 1 | 2022 | 87 | 0.190 |
Why?
|
| Doxorubicin | 2 | 2020 | 307 | 0.190 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 118 | 0.180 |
Why?
|
| Acrylamides | 1 | 2020 | 18 | 0.180 |
Why?
|
| Ifosfamide | 1 | 2020 | 37 | 0.180 |
Why?
|
| Ventricular Function, Left | 2 | 2022 | 500 | 0.180 |
Why?
|
| Atrial Function, Left | 1 | 2020 | 27 | 0.180 |
Why?
|
| Uncertainty | 1 | 2021 | 98 | 0.180 |
Why?
|
| Anthracyclines | 1 | 2020 | 42 | 0.180 |
Why?
|
| Aminopyridines | 1 | 2020 | 53 | 0.180 |
Why?
|
| p21-Activated Kinases | 1 | 2020 | 59 | 0.180 |
Why?
|
| Etoposide | 1 | 2020 | 119 | 0.180 |
Why?
|
| Mice | 11 | 2024 | 17637 | 0.170 |
Why?
|
| Cell Proliferation | 6 | 2024 | 2315 | 0.170 |
Why?
|
| ras Proteins | 1 | 2020 | 136 | 0.170 |
Why?
|
| Biomarkers, Tumor | 4 | 2020 | 1431 | 0.170 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 665 | 0.170 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2019 | 39 | 0.170 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2021 | 131 | 0.170 |
Why?
|
| Vincristine | 1 | 2020 | 208 | 0.170 |
Why?
|
| Echocardiography, Doppler | 1 | 2020 | 172 | 0.170 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 129 | 0.170 |
Why?
|
| Pyrroles | 1 | 2020 | 177 | 0.160 |
Why?
|
| Radiation Injuries | 1 | 2020 | 142 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 178 | 0.150 |
Why?
|
| beta Catenin | 1 | 2019 | 208 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1119 | 0.150 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 422 | 0.150 |
Why?
|
| Pyrazoles | 1 | 2020 | 301 | 0.150 |
Why?
|
| Heart Atria | 1 | 2020 | 308 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 413 | 0.150 |
Why?
|
| Cardiomyopathies | 1 | 2022 | 481 | 0.140 |
Why?
|
| Bone Marrow | 1 | 2019 | 319 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2017 | 480 | 0.140 |
Why?
|
| Bone and Bones | 1 | 2019 | 262 | 0.140 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 1227 | 0.130 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2017 | 155 | 0.130 |
Why?
|
| Prognosis | 3 | 2021 | 4492 | 0.130 |
Why?
|
| Sarcoma, Experimental | 1 | 2015 | 16 | 0.130 |
Why?
|
| Treatment Outcome | 6 | 2024 | 12036 | 0.130 |
Why?
|
| Heart Diseases | 1 | 2020 | 479 | 0.130 |
Why?
|
| Female | 13 | 2024 | 64937 | 0.130 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 471 | 0.130 |
Why?
|
| Heart Transplantation | 1 | 2022 | 854 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1234 | 0.120 |
Why?
|
| Biopsy | 1 | 2019 | 1251 | 0.120 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 217 | 0.120 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 150 | 0.120 |
Why?
|
| Echocardiography | 1 | 2020 | 1067 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 4984 | 0.120 |
Why?
|
| Infant | 3 | 2019 | 12347 | 0.120 |
Why?
|
| Male | 13 | 2024 | 59575 | 0.120 |
Why?
|
| Animals | 10 | 2023 | 33891 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 187 | 0.120 |
Why?
|
| Parents | 1 | 2021 | 1013 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 1076 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 675 | 0.110 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 1022 | 0.110 |
Why?
|
| Young Adult | 5 | 2024 | 8805 | 0.100 |
Why?
|
| Receptor, EphA2 | 1 | 2012 | 26 | 0.100 |
Why?
|
| Sarcoma | 1 | 2015 | 197 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 1000 | 0.100 |
Why?
|
| Apoptosis | 4 | 2020 | 1792 | 0.100 |
Why?
|
| Luminescent Measurements | 1 | 2011 | 57 | 0.100 |
Why?
|
| Organic Chemicals | 1 | 2011 | 59 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2022 | 2077 | 0.100 |
Why?
|
| Spheroids, Cellular | 1 | 2011 | 59 | 0.090 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2011 | 125 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 713 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 354 | 0.090 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 257 | 0.090 |
Why?
|
| Fluorescent Dyes | 1 | 2011 | 261 | 0.090 |
Why?
|
| Heart Failure | 1 | 2022 | 2125 | 0.080 |
Why?
|
| Pediatrics | 1 | 2018 | 1139 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2012 | 327 | 0.080 |
Why?
|
| HEK293 Cells | 1 | 2011 | 746 | 0.080 |
Why?
|
| Transcriptome | 1 | 2015 | 906 | 0.080 |
Why?
|
| Adult | 4 | 2018 | 28743 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1082 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1301 | 0.080 |
Why?
|
| Genetic Therapy | 1 | 2012 | 707 | 0.080 |
Why?
|
| Osteoblasts | 2 | 2021 | 151 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2022 | 15878 | 0.060 |
Why?
|
| Mutation | 3 | 2022 | 5786 | 0.060 |
Why?
|
| Radiotherapy Dosage | 1 | 2024 | 185 | 0.060 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2023 | 22 | 0.060 |
Why?
|
| Survival Rate | 2 | 2017 | 2001 | 0.050 |
Why?
|
| Cell Respiration | 1 | 2021 | 24 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2020 | 3231 | 0.050 |
Why?
|
| Oxadiazoles | 1 | 2021 | 25 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 83 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 93 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 607 | 0.050 |
Why?
|
| Chromatin | 1 | 2024 | 551 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 2793 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2024 | 13837 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2021 | 288 | 0.050 |
Why?
|
| Osteogenesis | 1 | 2021 | 154 | 0.050 |
Why?
|
| Quinolines | 1 | 2021 | 96 | 0.050 |
Why?
|
| Cellular Senescence | 1 | 2021 | 158 | 0.040 |
Why?
|
| Piperidines | 1 | 2021 | 196 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2020 | 26 | 0.040 |
Why?
|
| Imidazoles | 1 | 2021 | 200 | 0.040 |
Why?
|
| Systole | 1 | 2020 | 197 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 192 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 549 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 140 | 0.040 |
Why?
|
| Observer Variation | 1 | 2020 | 297 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1276 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 438 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1250 | 0.040 |
Why?
|
| Cell Movement | 1 | 2020 | 839 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2021 | 1006 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 581 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 538 | 0.030 |
Why?
|
| Risk Factors | 2 | 2020 | 9868 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 278 | 0.030 |
Why?
|
| Caspase 2 | 1 | 2015 | 26 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 11 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 871 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 102 | 0.030 |
Why?
|
| Karyotyping | 1 | 2015 | 338 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 157 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2015 | 228 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 186 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 230 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 333 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 758 | 0.030 |
Why?
|
| Homozygote | 1 | 2015 | 534 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2779 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1475 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 5970 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 552 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 285 | 0.030 |
Why?
|
| K562 Cells | 1 | 2012 | 95 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 872 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2015 | 638 | 0.030 |
Why?
|
| Retroviridae | 1 | 2012 | 205 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1005 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 3305 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2012 | 237 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 298 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2012 | 237 | 0.020 |
Why?
|
| Recurrence | 1 | 2015 | 1412 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2015 | 843 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2022 | 4514 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2012 | 513 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 6176 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 2442 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2012 | 973 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2035 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 3780 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 4383 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 4310 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3455 | 0.010 |
Why?
|